Here is the design of a clinical trial:

Official Title: Phase II ,III Randomized Double Blind Parallel Arms Clinical Trial of Potential Role of Gum Arabic ( Acacia Senegal) as Immunomodulatory Agent Among COVID 19 Patients in Sudan

Included conditions:
- COVID 19

Study Armgroups:
- {'label': 'Intervention Group', 'type': 'EXPERIMENTAL', 'description': 'This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose', 'interventionNames': ['Dietary Supplement: Acacia Senegal']}
- {'label': 'Control group', 'type': 'PLACEBO_COMPARATOR', 'description': 'This group will be provided with pectin powder provided as one-gram-dose', 'interventionNames': ['Dietary Supplement: Pectin']}

Interventions:
- {'type': 'DIETARY_SUPPLEMENT', 'name': 'Acacia Senegal', 'description': 'Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks', 'armGroupLabels': ['Intervention Group'], 'otherNames': ['Gum Arabic']}
- {'type': 'DIETARY_SUPPLEMENT', 'name': 'Pectin', 'description': 'Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks', 'armGroupLabels': ['Control group']}

Primary Outcomes:
- {'measure': 'Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks )', 'description': 'Changes of the level of Tumor Necrosis Factor (TNF), interleukin IL8,IL6,IL10 from the baseline values', 'timeFrame': '4 weeks'}
- {'measure': 'Mortality rate', 'description': 'The percentage of deaths among COVID 19 patients received Gum Arabic compared to placebo', 'timeFrame': 'from the date of assignment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to two months'}

Please estimate the sample size based on the assumption: 
Not specified in the provided paragraph.
Numbers to be randomised (sample size)
          110 eligible patients will be randomly assigned to either GA (n=55) or placebo (n=55) groups.